|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial显示文摘 | GHEORGHIADE M GA337S WA O'CONNOR CM | 2004 | JAMA2004，291，16： | 1 |
| 2 | Chronic heart failure in the United States:a manifestation of coronary artery disease显示文摘 | Gheorghiade M Bonow RO | 1998 | Circulation1998，97，3： | 1 |
| 3 | Vasopressin Vrreceptor blockade 'with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial显示文摘 | GHEORGHIADE M NIAZI I OUYANG J | 2003 | Circulation2003，107，21： | 1 |
| 4 | Sur-rogate end points in heart failure trials显示文摘 | Gheorghiade M Adams K F Jr Gattis W A | 2003 | Am Heart J2003，145，2： | 1 |
| 5 | Vasopressin: a new target for the treatment of heart failure显示文摘 | Craig R Lee Michael L Watkins J.Herbert Patterson Wendy Gattis Christopher M O'Connor Mihai Gheorghiade Kirkwood F Adams | 2003 | American Heart Journal2003，，1： | 1 |
| 6 | Short-term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials显示文摘 | Gheorghiade M Konstam M A Burnett J J | 2007 | JAMA2007，297，12： | 1 |
| 7 | Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial显示文摘 | MARVIN K GHEORGHIADE M JR J | 2007 | JAMA2007，297，12： | 1 |
| 8 | Tolvaptan, a selective oral vasopressin V2 receptor antagonist, for hyponatremia显示文摘 | Schrier RW Gross P Gheorghiade M | 2006 | N Engl J Med2006，355，20： | 1 |
| 9 | Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia显示文摘 | GHEORGHIADE M GOTI'LIEB SS UDELSON JE | 2006 | Am J Cardiol2006，97，7： | 1 |
| 10 | Digoxin therapy in chronic heart failure显示文摘 | Gheorghiade M | 1997 | Cardiovasc Drugs Ther1997，11，1： | 1 |
| 11 | Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials显示文摘 | Gheorghiade M Konstam MA Burnett JC Jr | 2007 | JAMA2007，297，12： | 1 |
| 12 | Relationship be- tween admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: Ananalysis from the OPTIMIZE - HF registry显示文摘 | Gheorghiade M Abraham WT Albert NM | 2007 | Eur Heart J2007，28，8： | 1 |
| 13 | Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia显示文摘 | Schrier RW Gross P Gheorghiade M | 2006 | N Engl J Med2006，355，20： | 1 |
| 14 | B-type natriuretic peptide: From bench to bedside 显示文摘 | Adams KF Mathur VS Gheorghiade M | 2003 | Am Heart J2003，145，2： | 1 |
| 15 | Effects of tolvaptan,a vasopressin antagonist,in patients hospitalized with worsening heart failure:a randomized controlled trial显示文摘 | Gheorghiade M Gattis WA O′Connor CM | | 0，，16： | 1 |
| 16 | Short term clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure: results of the EVEREST clinical status trials显示文摘 | Gheorghiade M Konstam MA Burnett JC | 2007 | JAMA2007，297，12： | 1 |
| 17 | Congestion is an important diagnostic and therapeutic target in heart failure显示文摘 | Gheorghiade M Shin DD Thomas TO | 2006 | Rev Cardiovasc Med2006，7，1： | 1 |
| 18 | Chronic heart failure in the United States: A manifestation of coronary artery disease 显示文摘 | Bonow RO | 1998 | Circulation,1998;97:282~2891998，97，： | 1 |
| 19 | Effects of oral tolvaptan in patients hospitalized for worsening heart {ailure: the EVEREST Outcome Trial显示文摘 | Gheorghiade M Konstam MA Burnett JC Jr | 2007 | JAMA2007，297，12： | 1 |
| 20 | Vasopressin V2- receptor blockade with tolvaptan in patients with chronic heart failure 显示文摘 | GHEORGHIADE M NIAZI I OUYANG J | 2003 | Circulation2003，107，21： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员